The companies have entered into a preclinical research collaboration agreement to evaluate the therapeutic potential of combining their two IgG-modulating technologies.
The preclinical research collaboration is set up to explore the potential of combining imlifidase, Hansa’s IgG antibody-cleaving enzyme, and efgartigimod, argenx’s FcRn antagonist, which are both in development for indications known to be driven by disease-causing IgGs, states the company in a press release.
“Both parties will maintain exclusive rights to their respective technologies and products.”
A combination of imlifidase and efgartigimod could potentially be used in both the acute and chronic setting of autoimmune diseases and transplantation.
Under the preclinical research collaboration agreement, both parties will contribute equally in terms of resource allocation and will share all intellectual property and data developed through the collaboration. Both parties will maintain exclusive rights to their respective technologies and products.
Photo of Søren Tulstrup, CEO, Hansa Biopharma
